CeD is characterized by a strong and pathogenic response of CD4+ T-cells against deaminated gluten peptides and at the same time a B-cell mediated response against the same peptides and the self-protein TG2 [20]. The gene discussed is TGM2; the disease is cranioectodermal dysplasia.